Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.50 |
| ▸ | CTSK | P43235 | 1/20 | 0.49 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.46 |
| ▸ | GAA | P10253 | 1/20 | 0.46 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.46 |
| ▸ | HPGD | P15428 | 2/20 | 0.46 |
| ▸ | SHMT1 | P34896 | 3/20 | 0.46 |
| ▸ | SHMT2 | P34897 | 2/20 | 0.46 |
| ▸ | RAB9A | P51151 | 3/20 | 0.46 |
| ▸ | NPC1 | O15118 | 2/20 | 0.46 |
| ▸ | MAPT | P10636 | 2/20 | 0.46 |
| ▸ | TSHR | P16473 | 1/20 | 0.46 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.46 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.46 |
| ▸ | LMNA | P02545 | 1/20 | 0.45 |
| ▸ | HTT | P42858 | 1/20 | 0.44 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8249164 | 1.00 | KDM4E (0.50) | KDM4ECTSKALDH1A1GAAHSD17B10 | |
| SCHEMBL5869680 | 0.93 | CTSK (0.43) | KDM4ECTSKALDH1A1GAAHSD17B10 | |
| SCHEMBL8248710 | 0.93 | CTSK (0.43) | KDM4ECTSKALDH1A1GAAHSD17B10 | |
| SCHEMBL6925810 | 0.92 | ALDH1A1 (0.46) | KDM4ECTSKALDH1A1SHMT1SHMT2 | |
| SCHEMBL5869648 | 0.92 | ALDH1A1 (0.46) | KDM4ECTSKALDH1A1SHMT1SHMT2 | |
| SCHEMBL5869664 | 0.92 | ALDH1A1 (0.46) | KDM4ECTSKALDH1A1SHMT1SHMT2 | |
| SCHEMBL5869659 | 0.92 | ALDH1A1 (0.46) | KDM4ECTSKALDH1A1SHMT1SHMT2 | |
| SCHEMBL5870340 | 0.90 | MAPT (0.47) | KDM4ECTSKALDH1A1GAAHSD17B10 | |
| SCHEMBL8256297 | 0.90 | MAPT (0.47) | KDM4ECTSKALDH1A1GAAHSD17B10 | |
| SCHEMBL5870037 | 0.90 | MAPT (0.47) | KDM4ECTSKALDH1A1GAAHSD17B10 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 25 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120009183-A1 | METHOD FOR TREATMENT OF PANCREATITIS | ORE PHARMACEUTICALS INC. (US) | 2012-01-12 | — | — | US | claimed |
| US-20100204286-A1 | METHOD FOR REDUCING GASTROINTESTINAL ADVERSE EFFECTS OF CYTOTOXIC AGENTS | ORE PHARMACEUTICAL, INC. | 2010-08-12 | — | — | US | claimed |
| US-20090186014-A1 | METHOD FOR TREATMENT OF PANCREATITIS | ORE PHARMACEUTICALS INC. (US) | 2009-07-23 | — | — | US | claimed |
| EP-2059234-A1 | METHOD FOR REDUCING OR ALLEVIATING INFLAMMATION IN THE DIGESTIVE TRACT | Ore Pharmaceuticals Inc. (US) | 2009-05-20 | — | — | EP | claimed |
| US-20080234345-A1 | METHOD FOR REDUCING OR ALLEVIATING INFLAMMATION IN THE DIGESTIVE TRACT | GENE LOGIC INC. (US) | 2008-09-25 | — | — | US | claimed |
| WO-2008031014-A1 | METHOD FOR REDUCING OR ALLEVIATING INFLAMMATION IN THE DIGESTIVE TRACT | ORE PHARMACEUTICALS INC. (US) | 2008-03-13 | — | — | WO | claimed |
| US-7045532-B2 | ACE-2 modulating compounds and methods of use thereof | MILLENNIUM PHARMACEUTICALS, INC. (US) | 2006-05-16 | — | — | US | claimed |
| US-20040082496-A1 | ACE-2 modulating compounds and methods of use thereof | MILLENNIUM PHARMACEUTICALS, INC. | 2004-04-29 | — | — | US | claimed |
| US-6632830-B1 | Blood pressure related disease or disorder, cell proliferation disorder, kidney disorder, kinetensin associated disorder, inflammation associated disorder, or an allergic disorder | MILLENNIUM PHARMACEUTICALS, INC. | 2003-10-14 | — | — | US | claimed |
| US-11337909-B2 | Methods for modulating pigmentation by angiotensin-converting enzyme 2 modulation | MAX-DELBRÜCK-CENTRUM FÜR MOLEKULARE MEDIZIN IN DER HELMHOLTZ-GEMEINSCHAFT (DE) | 2022-05-24 | — | — | US | disclosed |
| US-20200360258-A1 | METHODS FOR MODULATING PIGMENTATION BY ANGIOTENSIN-CONVERTING ENZYME 2 MODULATION | MAX-DELBRÜCK-CENTRUM FÜR MOLEKULARE MEDIZIN IN DER HELMHOLTZ-GEMEINSCHAFT (DE) | 2020-11-19 | — | — | US | disclosed |
| EP-3717077-A1 | METHODS FOR MODULATING PIGMENTATION BY ANGIOTENSIN-CONVERTING ENZYME 2 MODULATION | Max-Delbrück-Centrum für Molekulare Medizin in der Helmholtz-Gemeinschaft (DE) | 2020-10-07 | — | — | EP | disclosed |
| US-20120009183-A1 | METHOD FOR TREATMENT OF PANCREATITIS | ORE PHARMACEUTICALS INC. (US) | 2012-01-12 | — | — | US | disclosed |
| US-20100204286-A1 | METHOD FOR REDUCING GASTROINTESTINAL ADVERSE EFFECTS OF CYTOTOXIC AGENTS | ORE PHARMACEUTICAL, INC. | 2010-08-12 | — | — | US | disclosed |
| US-7045532-B2 | ACE-2 modulating compounds and methods of use thereof | MILLENNIUM PHARMACEUTICALS, INC. (US) | 2006-05-16 | — | — | US | disclosed |
| US-20040082496-A1 | ACE-2 modulating compounds and methods of use thereof | MILLENNIUM PHARMACEUTICALS, INC. | 2004-04-29 | — | — | US | disclosed |
| US-6632830-B1 | Blood pressure related disease or disorder, cell proliferation disorder, kidney disorder, kinetensin associated disorder, inflammation associated disorder, or an allergic disorder | MILLENNIUM PHARMACEUTICALS, INC. | 2003-10-14 | — | — | US | disclosed |
| WO-2002039997-A2 | ACE-2 MODULATING COMPOUNDS AND USE THEREOF | MILLENNIUM PHARMACEUTICALS, INC. (US) | 2002-05-23 | — | — | WO | disclosed |
| EP-1183019-A2 | ACE-2 INHIBITING COMPOUNDS AND METHODS OF USE THEREOF | Millennium Pharmaceuticals, Inc. (US) | 2002-03-06 | — | — | EP | disclosed |
| WO-2000066104-A2 | ACE-2 INHIBITING COMPOUNDS AND METHODS OF USE THEREOF | MILLENNIUM PHARMACEUTICALS, INC. (US) | 2000-11-09 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090186014-A1 | METHOD FOR TREATMENT OF PANCREATITIS | AMY2A, PNLIP, ACE | KDM4E 4504/4885CTSK 52/4885ALDH1A1 2641/4885 |
| US-20040082496-A1 | ACE-2 modulating compounds and methods of use thereof | ACE, ACE2, AGTR2 | KDM4E 2662/4885CTSK 541/4885ALDH1A1 1305/4885 |
| US-20200360258-A1 | METHODS FOR MODULATING PIGMENTATION BY ANGIOTENSIN-CONVERTING ENZYME 2 MODULATION | ACE, ACE2, TYR | KDM4E 3071/4885CTSK 166/4885ALDH1A1 375/4885 |
| US-20120009183-A1 | METHOD FOR TREATMENT OF PANCREATITIS | AMY2A, PNLIP, ACE | KDM4E 4504/4885CTSK 52/4885ALDH1A1 2641/4885 |
| US-20080234345-A1 | METHOD FOR REDUCING OR ALLEVIATING INFLAMMATION IN THE DIGESTIVE TRACT | ACE, ACE2, CTRB2 | KDM4E 4209/4885CTSK 82/4885ALDH1A1 957/4885 |
| US-20100204286-A1 | METHOD FOR REDUCING GASTROINTESTINAL ADVERSE EFFECTS OF CYTOTOXIC AGENTS | ACE2, ACE, ACER2 | KDM4E 4178/4885CTSK 996/4885ALDH1A1 176/4885 |
| US-11337909-B2 | Methods for modulating pigmentation by angiotensin-converting enzyme 2 modulation | ACE, ACE2, TYR | KDM4E 3071/4885CTSK 166/4885ALDH1A1 375/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.